Methylphenidate Refill Guidelines for Established ADHD

Pre-Refill Assessment Requirements

The American Academy of Pediatrics recommends checking blood pressure and heart rate at each refill visit, as methylphenidate can cause cardiovascular effects including hypertension and tachyarrhythmias 1, 2
The American Academy of Pediatrics suggests monitoring height and weight regularly during ongoing treatment, though long-term data show minimal impact on growth velocity 3
The American Academy of Pediatrics recommends utilizing prescription drug monitoring programs to identify potential diversion activities, particularly in adolescents who are at highest risk 4, 5
The American Academy of Pediatrics advises considering nonstimulant alternatives if diversion concerns arise 4
The American Academy of Pediatrics recommends confirming ongoing symptom control and functional improvement in multiple settings to justify continued treatment 4

The American Academy of Pediatrics states that methylphenidate remains off-label for preschool-aged children (4-5 years) despite moderate evidence for safety and efficacy 4, 5, 6
The American Academy of Pediatrics recommends confirming behavioral interventions were tried first before any refill is provided for preschool-aged children 7, 6
The American Academy of Pediatrics suggests verifying moderate-to-severe dysfunction persists with symptoms lasting at least 9 months and manifesting in both home and other settings for preschool-aged children 4, 5, 6
The American Academy of Pediatrics advises using lower doses with smaller incremental increases due to slower metabolism in preschool-aged children 4, 5, 3
The American Academy of Pediatrics recommends screening for substance use before each refill for adolescents (12-18 years) 4, 5
The American Academy of Pediatrics suggests ensuring medication coverage extends to driving hours by using longer-acting formulations or late-afternoon short-acting doses for adolescents 4
The American Academy of Pediatrics advises monitoring closely for diversion to peers for adolescents 4, 5

The National Comprehensive Cancer Network recommends dose reduction and early-day scheduling to mitigate agitation and insomnia 1, 2

The National Comprehensive Cancer Network advises not refilling if patient develops uncontrolled hypertension, coronary artery disease, or tachyarrhythmias during treatment 1, 2
The American Academy of Pediatrics recommends discontinuing rather than refilling if no improvement occurs after one month of appropriate dosing for children whose symptoms no longer meet DSM-5 criteria for ADHD 4, 5